Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2019 Filed Jun 14, 2019 00:49 UTC |
High Katherine ADirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016947 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:05 UTC |
Bolzon Bradley J PhDDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016847 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-06-11 F2 · shares: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders. F2 · derivative.underlying_shares: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:07 UTC |
Behbahani AliDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0001209191-19-036843 · doc4.xml · derivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:04 UTC |
CAGNONI PABLO JDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016845 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:04 UTC |
George SimeonDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $43.52 | $0.00 |
DisclosureSEC source: 0000899243-19-016843 · doc4.xml · derivative · entry 1 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 20:16 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 50,000 | $45.00 | $2,250,000.00 |
DisclosureSEC source: 0000899243-19-016636 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:25 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 741 | $35.57 | $26,357.37 |
DisclosureSEC source: 0000899243-19-015475 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,801 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On June 1, 2019, 1,667 restricted stock units vested, and the reporting person forfeited 741 common shares to the issuer to satisfy tax withholding obligations. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:05 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-19-011567 · doc4.xml · derivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,058 Underlying: Common Shares · 20,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:05 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 20,000 | $42.03 | $840,600.00 |
DisclosureSEC source: 0000899243-19-011567 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,542 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:05 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 20,000 | $1.81 | $36,200.00 |
DisclosureSEC source: 0000899243-19-011567 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:11 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006647 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 250,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:17 UTC |
Klein Lawrence OttoChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006657 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 45,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:14 UTC |
TOMSICEK MICHAEL JOHNChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006653 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:14 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006652 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Shares · 65,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 65,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:12 UTC |
Ho Tony WSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006649 · doc4.xml · derivative · entry 2 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2029-03-05 F2 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:12 UTC |
Ho Tony WSee Remarks
|
GrantRestricted Stock Units | 10,000 | $40.87 | $408,700.00 |
DisclosureSEC source: 0000899243-19-006649 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,869 F1 · shares: This restricted stock unit award was granted on March 5, 2019 with respect to 10,000 Common Shares, with (i) 3,333 shares vesting on March 5, 2020, (ii) 3,333 shares vesting on March 5, 2021, and (iii) 3,334 shares vesting on March 5, 2022. Each restricted stock unit represents a contingent right to receive one CRSP Common Share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 22:59 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 3,500 | $42.03 | $147,105.00 |
DisclosureSEC source: 0000899243-19-006186 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 22:59 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 8,912 | $41.29 | $367,948.85 |
DisclosureSEC source: 0000899243-19-006186 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,507 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 22:59 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 64,115 | $40.24 | $2,580,186.36 |
DisclosureSEC source: 0000899243-19-006186 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,419 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:59 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 8,693 | $40.01 | $347,796.50 |
DisclosureSEC source: 0000899243-19-006186 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,534 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:57 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 748 | $39.97 | $29,897.56 |
DisclosureSEC source: 0000899243-19-006182 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,542 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On March 1, 2019, 1,667 restricted stock units vested, and the reporting person forfeited 748 common shares to the issuer to satisfy tax withholding obligations. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:10 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 14,780 | $40.00 | $591,232.52 |
DisclosureSEC source: 0000899243-19-005001 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,227 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.025, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 21:09 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 82,690 | $35.01 | $2,894,976.90 |
DisclosureSEC source: 0000899243-19-000956 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,048,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.105, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:09 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 17,310 | $35.09 | $607,407.90 |
DisclosureSEC source: 0000899243-19-000956 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,697 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:32 UTC |
Klein Lawrence OttoChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $29.87 | $0.00 |
DisclosureSEC source: 0000899243-19-000296 · doc4.xml · derivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-01-01 F3 · derivative.exercise_date: 25% of the option shall vest on January 2, 2020, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the final day of each month. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:32 UTC |
Klein Lawrence OttoChief Business Officer
|
GrantRestricted Stock Units | 20,000 | $29.87 | $597,400.00 |
DisclosureSEC source: 0000899243-19-000296 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Each restricted stock unit represents a contingent right to receive one CRSP common share. F2 · security: The restricted stock units shall vest in full on January 2, 2021, subject to continued employment with the company. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 21:34 UTC |
Vertex Pharmaceuticals (Europe) Ltd10% owner
VERTEX PHARMACEUTICALS INC / MA10% owner
|
PurchaseCommon Shares | 27,461 | $24.95 | $685,116.25 |
DisclosureSEC source: 0001209191-18-064322 · doc4.xml · nonDerivative · entry 2 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,380,940 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F3 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 and $25.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 21:34 UTC |
Vertex Pharmaceuticals (Europe) Ltd10% owner
VERTEX PHARMACEUTICALS INC / MA10% owner
|
PurchaseCommon Shares | 12,737 | $24.89 | $317,077.43 |
DisclosureSEC source: 0001209191-18-064322 · doc4.xml · nonDerivative · entry 1 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,353,479 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F2 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.69 and $25.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 21:35 UTC |
Vertex Pharmaceuticals (Europe) Ltd10% owner
VERTEX PHARMACEUTICALS INC / MA10% owner
|
PurchaseCommon Shares | 53,655 | $24.97 | $1,339,695.60 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 4 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,340,742 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F5 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.82 and $25.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 21:35 UTC |
Vertex Pharmaceuticals (Europe) Ltd10% owner
VERTEX PHARMACEUTICALS INC / MA10% owner
|
PurchaseCommon Shares | 11,742 | $23.18 | $272,139.64 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 3 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287,087 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F4 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.02 and $23.25. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 21:35 UTC |
Vertex Pharmaceuticals (Europe) Ltd10% owner
VERTEX PHARMACEUTICALS INC / MA10% owner
|
PurchaseCommon Shares | 2,603 | $22.91 | $59,646.96 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 2 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275,345 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F3 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 and $23.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 21:35 UTC |
Vertex Pharmaceuticals (Europe) Ltd10% owner
VERTEX PHARMACEUTICALS INC / MA10% owner
|
PurchaseCommon Shares | 22,742 | $22.58 | $513,477.97 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 1 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,272,742 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F2 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.46 and $22.70. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 21:22 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 69,925 | $29.70 | $2,077,101.15 |
DisclosureSEC source: 0000905718-18-000981 · crisprfm4_dec172018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,164,268 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive. F2 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 18, 2018 Filed Jan 18, 2019 21:32 UTC Amendment |
EMSTER KURT VONDirector
|
SaleCommon Shares | 62,925 | $29.70 | $1,869,168.25 |
DisclosureSEC source: 0000905718-19-000065 · crisprfm4a_dec192018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,171,268 F1 · shares: This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive. F3 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · balance_after: This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction. F4 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F5 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 21:22 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 3,009 | $33.17 | $99,797.10 |
DisclosureSEC source: 0000905718-18-000981 · crisprfm4_dec172018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,234,193 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.29 per share, inclusive. F2 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 21:29 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-18-030649 · doc4.xml · derivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,058 Underlying: Common Shares · 21,500 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 21:29 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 21,500 | $1.81 | $38,915.00 |
DisclosureSEC source: 0000899243-18-030649 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2018 Filed Dec 3, 2018 22:29 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 741 | $38.33 | $28,402.53 |
DisclosureSEC source: 0000899243-18-029962 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,790 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On December 1, 2018, 1,666 restricted stock units vested, and the reporting person forfeited 741 common shares to the issuer to satisfy tax withholding obligations. Read SEC document |
| November 21, 2018 Filed Dec 7, 2017 09:57 UTC |
CELGENE CORP /DE/10% owner
|
SaleCommon Stock | 80,000 | $19.25 | $1,540,000.00 |
DisclosureSEC source: 0001209191-17-064325 · doc4.xml · nonDerivative · entry 13 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See explanation of responses Disclosed balance after: 4,173,019 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from: $17.86 to $18.57 on 11/16/2017; $18.30 to $18.65 on 11/17/2017; $18.60 to $19.26 on 11/20/2017; $19.02 to $19.46 on 11/21/2017; $19.20 to $20.01 on 11/22/2017; $19.84 to $20.27 on 11/24/2017; $19.41 to $20.20 on 11/27/2017; $19.00 to $19.76 on 11/28/2017; $19.20 to $19.39 on 11/29/2017; $19.00 to $19.20 on 11/30/2017; $19.02 to $19.22 on 12/1/2017; and $19.20 to 19.64 on 12/4/2017, inclusive. The reporting person undertakes to provide any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. F3 · ownership.nature: Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. Read SEC document |
| September 01, 2018 Filed Sep 4, 2018 22:33 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 741 | $56.67 | $41,992.47 |
DisclosureSEC source: 0000899243-18-023753 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,531 F1 · kind: On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On September 1, 2018, 1,667 restricted stock units vested, and the reporting person forfeited 741 common shares to the issuer to satisfy tax withholding obligations. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 21:43 UTC |
Ho Tony WSee Remarks
|
Tax withholdingCommon Shares | 14,631 | $48.43 | $708,579.33 |
DisclosureSEC source: 0000899243-18-021415 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,869 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:43 UTC |
Ho Tony WSee Remarks
|
Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-021415 · doc4.xml · derivative · entry 3 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vest in two equal annual installments on 8/1/2018 and 8/1/2019. F2 · derivative.expiration_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vest in two equal annual installments on 8/1/2018 and 8/1/2019. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:43 UTC |
Ho Tony WSee Remarks
|
Exercise / conversionCommon Shares | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-021415 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 22:25 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,684 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · derivative · entry 6 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,333 Underlying: Common Shares · 1,684 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 22:25 UTC |
CAGNONI PABLO JDirector
|
SaleCommon Shares | 1,684 | $62.00 | $104,408.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 22:25 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionCommon Shares | 1,684 | $5.59 | $9,413.56 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 22:25 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,816 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,017 Underlying: Common Shares · 5,816 shares Expires 2025-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 22:25 UTC |
CAGNONI PABLO JDirector
|
SaleCommon Shares | 5,816 | $62.00 | $360,592.00 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 03, 2018 Filed Jul 5, 2018 22:25 UTC |
CAGNONI PABLO JDirector
|
Exercise / conversionCommon Shares | 5,816 | $5.59 | $32,511.44 |
DisclosureSEC source: 0000899243-18-019501 · doc4.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:46 UTC |
Behbahani AliDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0001209191-18-038217 · doc4.xml · derivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning May 30, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.